107 related articles for article (PubMed ID: 577177)
21. [Clinical--pharmacological problems of control--therapy with antiarrhythmic drugs (author's transl)].
Mazur M; Wisławska-Orłowska B
Przegl Lek; 1978; 35(9):735-7. PubMed ID: 715260
[No Abstract] [Full Text] [Related]
22. [Side effects and interactions of antianginal and antiarrhythmic drugs (author's transl)].
Dayer P
Ther Umsch; 1982 Feb; 39(2):96-102. PubMed ID: 7071790
[No Abstract] [Full Text] [Related]
23. [Antiarrhythmic effects and blood level of acebutolol as for oral administration (author's transl)].
Suzuki M; Terukina M; Akamatsu T; Suzuki K
Kokyu To Junkan; 1977 Sep; 25(9):813-22. PubMed ID: 918406
[No Abstract] [Full Text] [Related]
24. [Clinical experiences with a new orally effective antiarrhythmic agent (Aprindin)].
Breithardt G; Gleichmann U; Seipel L; Loogen F
Z Kardiol; 1974 May; 63(3):435-44. PubMed ID: 4608660
[No Abstract] [Full Text] [Related]
25. How to evaluate class III antiarrhythmic drug efficacy clinically: the benefits and shortcomings of the noninvasive approach.
Andresen D; Behrens S; Stern R; Brüggemann T; Schröder R
J Cardiovasc Pharmacol; 1992; 20 Suppl 2():S28-31. PubMed ID: 1279306
[TBL] [Abstract][Full Text] [Related]
26. [Pertinence of animal and human models in the evaluation of ventricular anti-arrhythmia agents].
Funck-Brentano C; Le Heuzey JY
Arch Mal Coeur Vaiss; 1991 Feb; 84 Spec No 2():15-20. PubMed ID: 1726994
[TBL] [Abstract][Full Text] [Related]
27. [Clinical evaluation of amiodarone hydrochloride as an anti-arrhythmia agent].
Malpartida F; Triola M; Huguet R; Sala J; Noguera J; Cordeiro B
Rev Med Univ Navarra; 1975; 19(1):143-9. PubMed ID: 1234780
[TBL] [Abstract][Full Text] [Related]
28. [Determination of plasma concentrations of anti-arrhythmia agents].
Flouvat B
Arch Mal Coeur Vaiss; 1981 Dec; 74 Spec No():47-55. PubMed ID: 6803701
[TBL] [Abstract][Full Text] [Related]
29. The utility of serum drug level monitoring during therapy with class III antiarrhythmic agents.
Follath F
J Cardiovasc Pharmacol; 1992; 20 Suppl 2():S41-3. PubMed ID: 1279308
[TBL] [Abstract][Full Text] [Related]
30. [Active metabolites of anti-arrhythmia drugs].
Matusewicz W
Postepy Hig Med Dosw; 1985; 39(2):133-49. PubMed ID: 3900963
[No Abstract] [Full Text] [Related]
31. [Side effects of anti-arrhythmia drugs].
Neugebauer A
Z Gesamte Inn Med; 1984 Jun; 39(11):249-52. PubMed ID: 6475169
[TBL] [Abstract][Full Text] [Related]
32. Clinical studies of Norpace (Part I).
Smith WS
Angiology; 1975 Jan; 26(1 Pt 2):124-31. PubMed ID: 1090212
[No Abstract] [Full Text] [Related]
33. [Electrophysiologic effects of intravenous cibenzoline succinate, a new class I antiarrhythmic agent].
Atarashi H; Iida K; Kou M; Hirayama Y; Gotoh M; Ino T; Katoh T; Hayakawa H
Kokyu To Junkan; 1988 Oct; 36(10):1119-24. PubMed ID: 3247527
[No Abstract] [Full Text] [Related]
34. Tocainide: a new drug for ventricular arrhythmias.
Volosin KJ; Greenspon AJ
Am Fam Physician; 1986 Jan; 33(1):233-5. PubMed ID: 3079938
[No Abstract] [Full Text] [Related]
35. [General principles for choosing an anti-arrhythmia preparation and the treatment procedure in cardiac rhythm disturbances].
Mazur NA
Klin Med (Mosk); 1982 May; 60(5):68-72. PubMed ID: 7109520
[No Abstract] [Full Text] [Related]
36. [Antiarrhythmic therapy--recent aspects of pharmacologic treatment].
Patten M; Meinertz T
Dtsch Med Wochenschr; 2005 May; 130(21):1325-9. PubMed ID: 15902621
[TBL] [Abstract][Full Text] [Related]
37. [Tape-recorded evaluation of a new antiarrhythmic drug].
Johansson BW
Lakartidningen; 1975 Nov; 72(46):4515-6. PubMed ID: 1105029
[No Abstract] [Full Text] [Related]
38. [New method for direct study of antiarrhythmic drugs in man. Electrophysiological effects and criteria for interpretation].
Domenichelli B; Manzoli U; Schiavoni G; Feraco E
Minerva Cardioangiol; 1974 Feb; 22(2):71-89. PubMed ID: 4820118
[No Abstract] [Full Text] [Related]
39. Clinical studies of Norpace (Part II).
Vismara L
Angiology; 1975 Jan; 26(1 Pt 2):132-6. PubMed ID: 1090213
[No Abstract] [Full Text] [Related]
40. Therapy with and assessment of class III antiarrhythmic agents in different patient populations.
Podrid PJ
J Cardiovasc Pharmacol; 1992; 20 Suppl 2():S44-58. PubMed ID: 1279309
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
